Multiple clinical and preclinical presentations at ash 2023 highlight vor bio's novel ehsc and car-t platform

Cambridge, mass., nov. 02, 2023 (globe newswire) -- vor bio (nasdaq: vor), a clinical-stage cell and genome engineering company, today announced that preclinical and clinical data supporting the company's novel platform and approach for treating acute myeloid leukemia (aml), will be presented at the 65th american society of hematology (ash) annual meeting & exposition, being held from december 9-12, 2023, in san diego, ca.
VOR Ratings Summary
VOR Quant Ranking